Top Markets
#1 Akedo Akedo +84.18%
#2 TENDIES TENDIES +73.28%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.58%
#5 Mubarak Mubarak +31.80%
#6 MultiversX MultiversX +27.43%
#7 Bitway Bitway +26.80%
#8 Cash Cat Cash Cat +24.01%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Classifica tra le azioni #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)

Categoria

Healthcare
Ricavi di Regulus Therapeutics Inc. (RGLS)
Ricavi nel Mar 2025 TTM: $340.00K
Secondo gli ultimi rapporti finanziari di Regulus Therapeutics Inc., i ricavi attuali dell'azienda (TTM) sono pari a $340.00K. Nel 2023, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2022, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Regulus Therapeutics Inc. da 2010 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 3,712,929.41%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,770,866.86%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 655,194.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 4,630,584.45%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH